Scenario:An NDA is submitted for a novel drug to treat sever…
Scenario:An NDA is submitted for a novel drug to treat severe, treatment-resistant systemic lupus erythematosus (SLE). The clinical safety review reveals a risk of severe, reversible neutropenia (a drop in white blood cells), but the drug achieves clinical remission in of patients who have failed all other therapies. Question:Applying the core regulatory mandate of the Office of New Drugs (OND), how will the review team approach this approval decision?
Read Details